Genentech, a member of the Roche Group, has received approval from the U.S. FDA for the use of Lucentis® (ranibizumab injection) 0.5 mg for the treatment of myopic choroidal neovascularization (mCNV).
The approval is reportedly based on the results of the Phase III RADIANCE study, which reportedly demonstrated treatment with Lucentis offered superior visual acuity gains in patients with mCNV compared to verteporfin photodynamic therapy (vPDT). At the end of three months, patients treated with Lucentis had an average visual acuity gain of more than 12 letters, compared to 1.4 letters for those treated with vPDT.
This approval reportedly marks the fifth FDA-approved indication for Lucentis, which was launched back in 2006.
Click here to read the full press release.